| Literature DB >> 22672324 |
Rene S Hendriksen1, Eija Hyytia-Trees, Chaiwat Pulsrikarn, Srirat Pornruangwong, Phattharaporn Chaichana, Christina Aaby Svendsen, Rafiq Ahmed, Matthew Mikoleit.
Abstract
BACKGROUND: Bacteremia due to Salmonella spp. is a life-threatening condition and is commonly associated with immune compromise. A 2009 observational study estimated risk factors for the ten most common non-typhoidal Salmonella (NTS) serovars isolated from Thai patients between 2002-2007. In this study, 60.8% of Salmonella enterica serovar Enteritidis isolates (n = 1517) were recovered from blood specimens and infection with Salmonella serovar Enteritidis was a statistically significant risk factor for bacteremia when compared to other NTS serovars. Based on this information, we characterized a subset of isolates collected in 2008 to determine if specific clones were recovered from blood or stool specimens at a higher rate. Twenty blood isolates and 20 stool isolates were selected for antimicrobial resistance testing (MIC), phage typing, PFGE, and MLVA. RESULT: Eight antibiogrammes, seven MLVA types, 14 XbaI/BlnI PFGE pattern combinations, and 11 phage types were observed indicating considerable diversity among the 40 isolates characterized. Composite analysis based on PFGE and MLVA data revealed 22 genotypes. Seven of the genotypes containing two or more isolates were from both stool and blood specimens originating from various months and zones. Additionally, those genotypes were all further discriminated by phage type and/or antibiogramme. Ninety percent of the isolates were ciprofloxacin resistant.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22672324 PMCID: PMC3583215 DOI: 10.1186/1471-2180-12-92
Source DB: PubMed Journal: BMC Microbiol ISSN: 1471-2180 Impact factor: 3.605
Figure 1A composite dendrogram based on PFGE and MLVA data containing 40 serotype Enteritidis isolates from Thai patients.
Frequency of the resistance profile per variable; specimen and geographical zone among serovar Enteritidis in Thai patients during 2008
| AMP-CIP-NAL | 19 | 8 (42) | 11 (58) | 7 (37) | 0 | 0 | 4 (21) | 5 (26) | 2 (11) | 1 (5) |
| CIP-NAL | 9 | 3 (33) | 6 (67) | 2 (22) | 2 (22) | 1 (11) | 0 | 2 (22) | 2 (22) | 0 |
| CIP-NAL-SMX-TET-TMP | 2 | 1 (50) | 1 (50) | 1 (50) | 0 | 0 | 0 | 1 (50) | 0 | 0 |
| AMP-CIP-COL-NAL | 2 | 1 (50) | 1 (50) | 1 (50) | 0 | 0 | 0 | 0 | 0 | 1 (50) |
| AMP-CIP-STR | 2 | 1 (50) | 1 (50) | 1 (50) | 0 | 0 | 0 | 1 (50) | 0 | 0 |
| AMP-CIP-SPE-STR | 1 | 1 (100) | 0 | 0 | 0 | 0 | 0 | 1 (100) | 0 | 0 |
| CIP-NAL-TET | 1 | 1 (100) | 0 | 1 (100) | 0 | 0 | 0 | 0 | 0 | 0 |
| Pan-susceptible | 4 | 4 (100) | 0 | 1 (25) | 0 | 1 (25) | 0 | 2 (50) | 0 | 0 |
| Total | 40 | 20 (50) | 20 (50) | 14 (35) | 2 (5) | 2 (5) | 4 (10) | 12 (30) | 4 (10) | 2 (5) |
Abbreviations: AMP, ampicillin; CIP, ciprofloxacin; COL, colistin; NAL, nalidixic acid; SPT, spectinomycin; STR, streptomycin; SMX, sulfamethoxazole; TET, tetracycline; TMP, trimethoprim.